Thursday, September 20, 2007


PALM BEACH GARDENS, Fla., Sep. 20, 2007 (Business Wire) -- EncounterCare Solutions (Pink Sheets:ECSL), an integrated healthcare company focused on health information technology, telemedicine (Electronic Health Records and Remote Patient Monitoring) and home healthcare services, announced today that it has signed a contract with Navigant Consulting, Inc. (NYSE:NCI), to perform a drug study focused on the diabetic pharmacy market using its Electronic Medical Data Exchange (EMDE).

Ronald W. Mills, Sr., President and CEO of EncounterCare, announced that the Navigant Consulting, Inc. agreement is an important milestone in ECSL's corporate development. The Electronic Medical Data Exchange (EMDE) is a multi-use medical information exchange created to allow participating medical providers to easily exchange important medical data and critical health information. The EMDE Exchange is not limited to any particular electronic health record, but rather serves as a clearing house of information for participating providers. The EMDE was first piloted as part of Building Blocks Home Pediatric Services, a wholly-owned subsidiary of EncounterCare Solutions, Inc. Mr. Mills further stated, 'The concept of the EMDE has received significant traction within the healthcare industry and is being beta-tested in multiple sites within the United States. Furthermore, expect EMDE to become an integral part of ECSL's Electronic House Call, which is our remote patient monitoring system.'

About EncounterCare Solutions, Inc.

EncounterCare Solutions, Inc. (ECSL - Pink Sheets), headquartered in Palm Beach Gardens, Florida, is an integrated healthcare company that operates its business through two divisions: the Healthcare Technology Division and the Healthcare Services Division. ECSL's three operating businesses offer a broad range of proprietary healthcare technology, products and services that address several substantial target markets, including: the Healthcare Information Technology market, the Healthcare Telemedicine market (Electronic Health Record and Electronic Medical Data Exchange), and the Homecare market. ECSL's Website: www.encountercare.com.

About Navigant Consulting

Navigant Consulting (NYSE:NCI) is a specialized independent consulting firm providing dispute, financial, regulatory and operational advisory services to government agencies, legal counsel and large companies facing the challenges of uncertainty, risk, distress and significant change. The Company focuses on industries undergoing substantial regulatory or structural change and on the issues driving these transformations. The Drug Study agreement with ECSL was commissioned by the Life Sciences Practice of Navigant Consulting's Business Advisory segment. More information about Navigant Consulting can be found at www.navigantconsulting.com.

Safe Harbor

Certain Statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Federal Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intends,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, including but not limited to, economic conditions, dependence on management, dilution to shareholders, lack of capital changes in laws or regulations, the affects of rapid growth upon the Company and the ability of management to effectively respond to the growth, demand for products and services of the Company, newly developing technologies, its ability to compete, conflicts of interest related to party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition, and the ability of the Company to obtain additional financing. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Newstex ID: BW-0001-19709851


Delivered by Newstex LLC
via theFinancials.com